Pediatrix announces leadership transitions

Pediatrix announces leadership transitions

FORT LAUDERDALE, Florida–(BUSINESS WIRE)–Pediatrix Medical Group, Inc. (NYSE: MD), the nation’s leading provider of highly specialized healthcare for women, babies and children, today announced that the company’s Board of Directors has named James D. Swift, MD, as chief executive officer, succeeding Mark S. Ordan, who was named executive chairman of the company’s board of directors and has served as chief executive officer since July 2020. Guy P Sansone, who previously served as chairman of the company’s board of directors since July 2020, has been appointed lead independent director. Each of these transitions will come into effect at the end of the year.

“During Mark’s two and a half years at Pediatrix, he and his seasoned management team have developed a focused return to women’s and children’s care, significantly strengthened our balance sheet and launched an expansion into primary and urgent care, while managing through a turbulent time for healthcare providers,” Sansone said. “The company’s stated goal has also been to reduce overhead while maintaining tight oversight of the organization.”

“We are very pleased to have Jim, an experienced physician leader, step into the role of CEO after years of leadership at Pediatrix,” continued Mr. Sansone. “Jim is surrounded by a strong and dedicated team, and our Board of Directors is confident and excited about our next chapter.”

Dr. Swift joined the Company in 2009 following the acquisition of a multi-state specialty pediatric practice, Children’s HealthCare Network, which he founded in 1996 and served as Chief Executive Officer. In 2013, Dr. Swift became Director of Development for Pediatrix after serving as Regional President, South Central Region, for the company’s Pediatrix division. He was named executive vice president and chief operating officer of the company in 2022.

Dr. Swift received her medical degree from the University of Health Sciences/Chicago School of Medicine and completed her residency training in Internal Medicine/Pediatrics at Loma Linda University Medical Center. He completed a fellowship in pediatric critical care at Harbor-UCLA Medical Center, Children’s Hospital of Orange County, and Martin Luther King Jr. Medical Center. Dr. Swift co-edited the clinical manual titled “Pediatric Hospital Medicine: Textbook of Inpatient Management”. At the time of its publication in 2007, it was the first manual intended for paediatricians practicing in hospital settings.

“It has been a privilege for me to lead this extraordinary organization as Chief Executive Officer,” Mr. Ordan said. “With such a talented team in place, a very focused strategy, as well as our strong financial position, I am confident that now is the right time to step into the CEO position. I look forward to continuing to work with Dr. Swift, our group of world-class clinicians and our extraordinarily dedicated team.

“I am honored to take on this role and to continue to work closely with so many dedicated and talented clinicians and staff,” said Dr. Swift. “During my 13 years at Pediatrix, I have had the opportunity, both as a staff physician and as an executive, to see firsthand the outstanding care our clinicians provide to women, infants, children and to young adults. It was also an incredible privilege to work alongside Mark to refine our vision for the organization. I look forward to working with our management team, Mark and the Board, to strengthen our culture of care and continue our growth in the future.


Pediatrix® Medical Group, Inc. (NYSE: MD) is the nation’s leading provider of medical services. Clinicians affiliated with Pediatrix are committed to providing coordinated, compassionate, and clinically excellent services to women, babies, and children across the continuum of care, in both hospital and office settings. Specialties include obstetrics, maternal-fetal medicine and neonatology supplemented by more than 20 pediatric sub-specialties, as well as a new expanded area of ​​pediatric primary care and emergency clinics. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality improvement and safety initiatives. The physician-led company was founded in 1979 as a one-stop neonatology practice and today provides its highly specialized and often critical care services through more than 4,800 affiliated physicians and other clinicians in 37 states and in Puerto Rico. To learn more about Pediatrix, visit or follow us on Facebook, Instagram, LinkedIn, Twitter and the Pediatrix blog. Investment information is available at

Certain statements and information contained in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Litigation Act”). securities”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements regarding the Company’s objectives, plans and strategies, and all statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terms such as “believe”, “hope”, “may”, “anticipate”, “should”, “intend”, “plan”, “will”, “expect”. to”, “estimate”, “project”, “positioned”, “strategy” and similar expressions, and are based on assumptions and assessments made by the management of the Company in light of its experience and its perception of trends historical, current conditions, expected future developments and other factors it believes to be appropriate. All forward-looking statements contained in this press release are made as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from the forward-looking statements are described in the company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, including including the sections titled “Risk Factors,” as well as the company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the company’s name change; the impact of the COVID-19 pandemic on the Company, its financial condition and results of operations; the effects of economic conditions on the Company’s business; the effects of the Affordable Care Act and potential amendments thereto or its repeal; the Company’s relationships with government-sponsored or funded health care programs, including Medicare and Medicaid, and with organi managed care stations and commercial health insurance payers; the impact of surprise billing legislation and its implementation; the Company’s ability to meet the terms of its debt financing agreements; the Company’s transition to a third-party revenue cycle management provider; the impact of the disposal of the Company’s anesthesiology and radiology medical groups; the impact of managerial transitions; the timing and contribution of future acquisitions; the effects of share buybacks; and the effects of the Company’s transformation initiatives, including its reorientation and growth strategy for its pediatrics and obstetrics businesses.

#Pediatrix #announces #leadership #transitions

Leave a Comment

Your email address will not be published. Required fields are marked *